Predictive Biology
Private Company
Total funding raised: $2.5M
Overview
Predictive Biology is a private, pre-clinical stage biotech firm developing a proprietary in vitro genetics platform for target discovery and preclinical pharmacology. Its core asset is a large, genetically diverse panel of over 1,000 mouse embryonic stem cell lines derived from Diversity Outbred mice, which it differentiates into various cell types and organoids for high-throughput phenotypic and molecular QTL mapping. The company operates primarily as a platform and services partner for pharmaceutical and biotech companies, focusing on neuroscience, toxicology, and drug mechanism evaluation, and is currently pre-revenue with SBIR grant funding supporting some programs.
Technology Platform
Proprietary in vitro genetics platform utilizing a panel of over 1,000 genetically diverse mouse embryonic stem cell lines derived from Diversity Outbred mice. The platform combines stem cell differentiation (2D and 3D organoid models), high-throughput phenotypic screening, and multi-omics analysis (single-cell RNAseq, ATACseq, proteomics, imaging) to map QTLs for drug response and disease phenotypes, identifying and validating causal drug targets.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Predictive Biology competes with other functional genomics and stem cell-based discovery platforms, such as those from Charles River Laboratories (via its Citox acquisition), StemoniX, and Neurosetta, as well as large genomic CROs like GenScript and Lonza. Its unique differentiator is the combination of a large, genetically diverse DO mouse stem cell biobank with integrated multi-omics phenotyping for in vitro QTL mapping.